Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wrobel, MD PhD, Adam Nowicki, Bartosz Pula, Norbert Grząśko, Justyna Rybka, Paweł J. Robak, MD, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Katarzyna Brzeźniakiewicz-Janus, MDPhD, Jarosław Czyż, Krzysztof Warzocha, Dominik Dytfeld

Blood (2017) 130 (Supplement 1): 5404.

https://doi.org/10.1182/blood.V130.Suppl_1.5404.5404

Published: 2017

Journal Articles

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Tomasz Szczepaniak, MD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Joanna Czerwinska-Rybak, MSc, Adam Nowicki, MD PhD, Monika Joks, MD PhD, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2016) 128 (22): 2092.

https://doi.org/10.1182/blood.V128.22.2092.2092

Published: 2016

Journal Articles

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Adam Nowicki, MD, Joanna Czerwinska-Rybak, MSc, Monika Joks, MD PhD, Tomasz Szczepaniak, MD PhD, Bochenek Maciej, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2015) 126 (23): 2986.

https://doi.org/10.1182/blood.V126.23.2986.2986

Published: 2015

Journal Articles

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Blood (2014) 124 (21): 2564.

https://doi.org/10.1182/blood.V124.21.2564.2564

Published: 2014

Journal Articles

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Lidia Gil, MD PhD, Jan Styczynski, MD, PhD, Agnieszka Piekarska, MD PhD, Beata Jakubas, MD PhD, Katarzyna Drabko, MD PhD, Tomasz Wrobel, prof., Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Dominik Dytfeld, MD PhD, Adam Nowicki, MD, Patrycja Mensah-Glanowska, MD PhD, Wanda Knopinska-Posluszny, MD, PhD, Maria Bieniaszewska, MD PhD, Mariusz Wysocki, MD, PhD, Andrzej Hellmann, MD, PhD, Aleksander Skotnicki, Jerzy Kowalczyk, Kazimierz Kuliczkowski, MD PhD, prof., Mieczyslaw Komarnicki, MD PhD

Blood (2011) 118 (21): 3109.

https://doi.org/10.1182/blood.V118.21.3109.3109

Published: 2011

Journal Articles

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Anna Czyz, Adam Nowicki, Lidia Gil, Dominik Dytfeld, Anna Lojko-Dankowska, Jan Styczynski, PhD, Mieczyslaw Komarnicki

Blood (2010) 116 (21): 2822.

https://doi.org/10.1182/blood.V116.21.2822.2822

Published: 2010

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Anna Czyz, Anna Lojko, Lidia Gil, Dominik Dytfeld, Danuta Drozdowska, Adam Nowicki, Maria Kozlowska, Krzysztof Sawinski, Jan Styczynski, Mieczyslaw Komarnicki

Blood (2009) 114 (22): 3406.

https://doi.org/10.1182/blood.V114.22.3406.3406

Published: 2009

Journal Articles

Polish Myelodysplastic Syndromes Registry- Report of 15 Months of Activity.

Blood (2009) 114 (22): 4848.

https://doi.org/10.1182/blood.V114.22.4848.4848

Published: 2009

NARROW

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Polish Myelodysplastic Syndromes Registry- Report of 15 Months of Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only